Intercept Pharmaceuticals is part of the healthcare sector and is in the biotechnology industry. The company CEO is Mark Pruzanski. Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need.



Previous Intraday Performance:

The ICPT shares had a previous change of 3.61% which opened at 84.20 and closed at 86.75. It moved to an intraday high of 87.83 and a low of 83.70.

SeekingAlpha:  Intercept prices equity offerings

Historical Performance:

Over the last five trading days, ICPT shares returned -0.94% and in the past 30 trading days it returned -23.88%. Over three months, it changed -21.39%. In one year it has changed 20.99% and within that year its 52-week high was 133.74 and its 52-week low was 65.63. ICPT stock is 32.18% above its 52 Week Low.

Our calculations result in a 200 day moving average of 105.73 and a 50 day moving average of 101.03. Right now, ICPT stock is trading -17.95% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Intercept prices equity offerings

Liquidity:

The company has a market cap of $2.6b with 29.8m shares outstanding and a float of 29.0m shares. Trading volume was 747,591 shares and has experienced an average volume of 1,094,955 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.

Earnings:

The last annual reported EPS for Intercept Pharmaceuticals was -10.95 which ended on 31st of December 2018. Based on 11 analyst estimates, the consensus EPS for the next quarter is -2.58.

Base on our calculations, the intrinsic value per share is 157.80, which means it might be undervalued and has a margin of safety of 45.02%

The next earnings report will be: 06-17-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Intercept Pharmaceuticals; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 14.30% over the last twelve months.



Indicators Also to Watch:

I calculated the beta to be 1.47

Business Wire:  Ladenburg Reports First Quarter 2019 Financial Results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 619.63%, return on assets is -79.78%, price-to-sales is 12.72 and price-to-book is 130.63.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here